ABSTRACT
Childhood cancer survivors are at risk for ongoing health risks related to their initial treatment. One potential long-term complication following radiation is the development of secondary tumors, including peripheral nerve tumors, such as schwannomas. We present three adolescent and young adult (AYA)-aged survivors of pediatric cancer (22-40 years), followed in our AYA survivorship clinic. Each was found to have a schwannoma many years following total body irradiation for a childhood primary malignancy. We highlight a late effect of low-dose total body irradiation as well as the importance of long-term monitoring in this population.
Subject(s)
Cancer Survivors , Myelodysplastic Syndromes/radiotherapy , Neoplasms, Radiation-Induced/pathology , Neurilemmoma/pathology , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Adult , Female , Humans , Male , Myelodysplastic Syndromes/pathology , Neoplasms, Radiation-Induced/etiology , Neoplasms, Radiation-Induced/therapy , Neurilemmoma/etiology , Neurilemmoma/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Prognosis , Whole-Body Irradiation/adverse effects , Young AdultSubject(s)
Antibodies, Monoclonal/therapeutic use , Antineoplastic Agents/therapeutic use , Leukemia, Myeloid, Acute/radiotherapy , Myelodysplastic Syndromes/radiotherapy , Antigens, CD20 , Clinical Trials as Topic , Follow-Up Studies , Humans , Leukemia, Myeloid, Acute/metabolism , Myelodysplastic Syndromes/metabolism , Retreatment , Treatment OutcomeABSTRACT
ACE inhibitors and ARBs (angiotensin receptor blockers) have been shown to attenuate radiation injuries in animal models of lethal gamma irradiation. These two classes of drug act by curtailing the actions of angiotensin II-linked inflammatory pathways that are up-regulated during gamma radiation in organ systems such as the brain, lung, kidney, and bone marrow. ACE inhibitors inhibit ACE and attenuate the formation of angiotensin II from angiotensin I; ARBs block the angiotensin AT1 receptor and attenuate the actions of angiotensin II that are elicited through the receptor. DAA-I (des-aspartate-angiotensin I), an orally active angiotensin peptide, also attenuates the deleterious actions of angiotensin II. It acts as an agonist on the angiotensin AT1 receptor and elicits responses that oppose those of angiotensn II. Thus, DAA-I was investigated for its anticipated radioprotection in gamma irradiated mice. DAA-I administered orally at 800 nmole/kg/day for 30 days post exposure (6.4 Gy) attenuated the death of mice during the 30-day period. The attenuation was blocked by losartan (50 nmole/kg/day, i.p.) that was administered sequential to DAA-I administration. This shows that the radioprotection was mediated via the angiotensin AT1 receptor. Furthermore, the radioprotection correlated to an increase in circulating PGE2 of surviving animals, and this suggests that PGE2 is involved in the radioprotection in DAA-I-treated mice. At the hematopoietic level, DAA-I significantly improved two syndromes of myelosuppression (leucopenia and lymphocytopenia), and mice pre-treated with DAA-I prior to gamma irradiation showed significant improvement in the four myelodysplastic syndromes that were investigated, namely leucopenia, lymphocytopenia, monocytopenia and thrombocytopenia. Based on the known ability of PGE2 to attenuate the loss of functional hematopoietic stem and progenitor cells in radiation injury, we hypothesize that PGE2 mediated the action of DAA-I. DAA-I completely attenuated the increase in circulating level of two inflammatory cytokines, TNFα and IL-6, in irradiated mice; and this shows that DAA-I exerted additional anti-inflammatory actions, which could also have contributed to its radioprotection. These findings show that DAA-I acts via a novel mechanism of action on the angiotensin AT1 receptor to specifically release PGE2, which mediates radioprotection in the gamma irradiated mice.
Subject(s)
Angiotensin I/analogs & derivatives , Gamma Rays/adverse effects , Myelodysplastic Syndromes/drug therapy , Radiation-Protective Agents/pharmacology , Angiotensin I/pharmacology , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Animals , Dinoprostone/metabolism , Female , Interleukin-6/metabolism , Losartan/pharmacology , Mice , Mice, Inbred BALB C , Myelodysplastic Syndromes/metabolism , Myelodysplastic Syndromes/radiotherapy , Receptor, Angiotensin, Type 1/metabolism , Tumor Necrosis Factor-alpha/metabolismABSTRACT
The combination of reduced-intensity conditioning, (188)rhenium anti-CD66 radioimmunotherapy, and in vivo T cell depletion was successfully applied in elderly patients with acute myeloid leukemia or myelodysplastic syndrome. Within a prospective phase II protocol, we investigated whether a dose reduction of alemtuzumab (from 75 mg to 50 mg MabCampath) would improve leukemia-free survival by reducing the incidence of relapse. Fifty-eight patients (median age, 67 years; range, 54 to 76) received radioimmunotherapy followed by fludarabine 150 mg/m(2) and busulfan 8 mg/kg combined with either 75 mg (n = 26) or 50 mg (n = 32) alemtuzumab. Although we observed a trend towards a shorter duration of neutropenia in the 50 mg group (median, 19 versus 21 days; P = .07), the time from transplantation to neutrophil and platelet engraftment as well as the overall incidence of engraftment did not differ. The incidence of severe acute graft-versus-host disease tended to be higher after the lower alemtuzumab dose (17% versus 4%; P = .15). No significant differences in the cumulative incidences of relapse (38% versus 35%; P = .81) or nonrelapse mortality (46% versus 27%; P = .31) were observed. Accordingly, disease-free and overall survival were not significantly different between groups. Although the feasibility of radioimmunotherapy plus reduced-intensity conditioning could be demonstrated in elderly patients, the dose reduction of alemtuzumab had no positive impact on overall outcome.
Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Antibodies, Monoclonal/therapeutic use , Graft vs Leukemia Effect , Immunoconjugates/therapeutic use , Leukemia, Myeloid, Acute/therapy , Lymphocyte Depletion/methods , Myelodysplastic Syndromes/therapy , Radioimmunotherapy , Radioisotopes/therapeutic use , Rhenium/therapeutic use , T-Lymphocytes/immunology , Transplantation Conditioning/methods , Aged , Alemtuzumab , Allografts , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal, Humanized/administration & dosage , Antigens, CD/immunology , Antigens, Neoplasm/immunology , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Busulfan/administration & dosage , Cell Adhesion Molecules/immunology , Combined Modality Therapy , Disease-Free Survival , Dose-Response Relationship, Drug , Feasibility Studies , Female , Graft vs Host Disease/epidemiology , Graft vs Host Disease/etiology , Humans , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/radiotherapy , Lymphocyte Depletion/adverse effects , Male , Middle Aged , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/radiotherapy , Neutropenia/etiology , Prospective Studies , Transplantation Conditioning/adverse effects , Vidarabine/administration & dosage , Vidarabine/analogs & derivativesABSTRACT
Although reduced-intensity conditioning (RIC) has been increasingly used in patients with myelodysplastic syndrome (MDS) to reduce transplant-related mortality, a high relapse rate in RIC remains an unresolved problem. Considering the additive antileukemic effect of low-dose total body irradiation (TBI), we evaluated the feasibility of combining RIC regimens with low-dose TBI in de novo MDS. The RIC regimen combined with low-dose TBI in this study consisted of fludarabine (150 mg/m(2)), intravenous busulfan (6.4 mg/kg), and TBI (400 cGy). Antithymocyte globulin was used to overcome HLA mismatching. A total of 31 subjects were recruited with a median age of 39 years (range 19-63). The patients received transplants from siblings (n = 20) or unrelated donors (n = 11). All patients rapidly achieved full-donor chimerism. At a median follow-up for survivors of 35 months (range 6.0-54.9), the 3-year overall survival, event-free survival, transplantation-related mortality, and relapse rates were 67.6, 63.2, 20.5 and 11.4%, respectively. The 3-year cumulative incidence of acute (grades II-IV) and chronic extensive graft-versus-host disease in patients who survived at least 100 days was 39.2 and 44.6%, respectively. These results suggest that an RIC combined with low-dose TBI may be a feasible therapeutic approach for treating de novo MDS.
Subject(s)
Myelodysplastic Syndromes/therapy , Transplantation Conditioning/methods , Whole-Body Irradiation , Adult , Combined Modality Therapy , Female , Graft vs Host Disease , Humans , Male , Middle Aged , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/radiotherapy , Myelodysplastic Syndromes/surgery , Radiotherapy Dosage , Stem Cell Transplantation , Treatment OutcomeABSTRACT
AIM: Tumour necrosis factor-alpha (TNF-alpha) serum levels may increase due to intensive conditioning regimes with high-dose-chemotherapy and total body irradiation (TBI) before stem cell transplantation. This increases the risk for developing acute graft versus host disease (aGvHD) after stem cell transplantation. In this prospective study we investigated the influence of radioimmunotherapy with 188Re-CD-66-mAb on changes on TNF-alpha serum levels. PATIENTS, METHODS: In 18 patients we measured TNF-alpha before and up to 96 hours after radioimmunotherapy, in 2 patients in addition following TBI, in 9 patients also following chemotherapy. For measuring TNF-alpha we used an automated immunochemiluminescence assay (Immulite 1000 DPC Biermann, Bad Nauheim). The mean follow up period to record incidence of aGVHD was 100 days after stem cell transplantation. RESULTS: Compared to the basal levels before, the levels of TNF-alpha after conditioning with 188Re-CD-66-mAb did not increase significantly and remained in the physiological range. In contrast, these initial physiological cytokine levels increased and became pathological following 48 h after total body irradiation (13.2+/-6.6 pg/ml) and chemotherapy (10.8+/-15.7 pg/ml). In our study we found a low incidence of aGvHD (22.2%, n=4/18). CONCLUSION: These results demonstrate that additional conditioning therapy with 188Re-CD-66-mAb does not increase proinflammatory cytokine levels of TNF-alpha. This finding may indicate that additive radioimmunotherapy may not be a significant factor for increasing the rate of conditioning-associated aGvHD.
Subject(s)
Leukemia, Myeloid, Acute/radiotherapy , Myelodysplastic Syndromes/radiotherapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Radioimmunotherapy/methods , Radioisotopes/therapeutic use , Rhenium/therapeutic use , Stem Cell Transplantation/methods , Tumor Necrosis Factor-alpha/blood , Adult , Antibodies, Monoclonal/therapeutic use , Antigens, CD/immunology , Cell Adhesion Molecules/immunology , Child , Female , Humans , Leukemia, Myeloid, Acute/surgery , Male , Middle Aged , Myelodysplastic Syndromes/surgery , Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery , Young AdultABSTRACT
PURPOSE: The purpose of this study was to evaluate the results of two sequential total body irradiation (TBI) regimens, especially focusing on pulmonary complications. MATERIALS AND METHODS: Patients with malignant disease who underwent TBI followed by bone marrow transplantation were retrospectively reviewed. There were 86 patients (51 males, 35 females). Altogether, 36 patients were treated on twice-daily fractions of 2 Gy for 3 days to a total 12 Gy (group A). Another 50 patients were treated on once-daily fractions of 2.4 or 3.0 Gy for 4 or 5 days to a total 12 Gy (group B). RESULTS: The 5-year overall survival rate was 49.2%, and relapse-free survival was 44.3%. There were no significant differences between the two groups regarding overall survival (P = 0.1237) or relapse-free survival (P = 0.1548). Two patients in group A had interstitial pneumonitis of grade 3 or higher severity compared with three patients in group B. There was no significant difference between patients in group A (5-year probability rate was 7.6%) and patients in group B (5-year probability rate was 13.9%) (P = 0.9519). CONCLUSION: We concluded that our once-daily TBI regimen is feasible and had the benefit of reducing the complexity of TBI. We believe that further investigation of the TBI regimen is needed.
Subject(s)
Bone Marrow Transplantation , Leukemia/radiotherapy , Lymphoma/radiotherapy , Multiple Myeloma/radiotherapy , Myelodysplastic Syndromes/radiotherapy , Whole-Body Irradiation/methods , Adolescent , Adult , Child , Combined Modality Therapy , Disease-Free Survival , Female , Humans , Leukemia/mortality , Leukemia/surgery , Lung Diseases, Interstitial/epidemiology , Lung Diseases, Interstitial/etiology , Lymphoma/mortality , Lymphoma/surgery , Male , Middle Aged , Multiple Myeloma/mortality , Multiple Myeloma/surgery , Myelodysplastic Syndromes/mortality , Myelodysplastic Syndromes/surgery , Whole-Body Irradiation/adverse effectsABSTRACT
O efeito leucemogênico dos agentes quimioterápicos após o tratamento para neoplasias é bem conhecido. Síndrome mielodisplásica secundária a quimio ou radioterapia, também denominada relacionada à terapia (SMD-t), geralmente ocorre quatro a sete anos após a exposição inicial ao agente quimio ou radioterápico, acomete habitualmente pacientes jovens, apresenta alta incidência de transformação para leucemia mielóide aguda (LMA), está associada a citopenias severas, displasia das três linhagens, celularidade medular reduzida e fibrose, e anormalidades citogenéticas em até 80 por cento dos casos. As anormalidades mais freqüentes envolvem os cromossomos 5 e 7. No tocante à quimioterapia, os agentes alquilantes são as drogas mais comumente associadas com SMD-t. Quimioterápicos em altas doses usados como parte de regimes de condicionamento para transplantes de medula óssea e radioterapia, além dos esquemas COPP/ABV e BEACOPP, estão associados com SMD-t. Recentemente, drogas como azatioprina, cladribina e rituximab também foram relacionadas à SMD-t. Devido ao aumento da sobrevida de pacientes acometidos por neoplasias malignas, a SMD-t surge como efeito mutagênico desses tratamentos e confere prognóstico desfavorável.
The leukaemogenic effect of chemotherapeutic agents after treatment for other malignancies have been well described. Myelodysplastic syndrome secondary to chemo- and radiotherapy (MDS-t) usually develops four to seven years after the initial exposure to chemotherapy frequently involving young patients, shows a high incidence of transformation to AML, is associated with severe cytopenias, trilineage dysplasia, reduced marrow cellularity and fibrosis, and presents an incidence of chromosomal abnormalities of up to 80 percent of the cases. The most common abnormalities are related to chromosomes 5 and 7. Alkylating agents have been considered the most common drugs associated with MDS-t. High dose chemotherapy used as part of the conditioning regimen prior to bone marrow transplantation as well as traditional regimens such as COPP/ABV and BEACOPP have also been associated with MDS-t. Recently, drugs such as azathioprine, rituximab and cladribine have been reported as causes too. Due to the increasing survival of patients suffering from other malignancies, MDS-t results as a mutagenic effect of these therapies and is related to poor prognosis.
Subject(s)
Humans , Myelodysplastic Syndromes , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/radiotherapyABSTRACT
In a phase I-II study for patients aged 55-65 years, we employed radioimmunotherapy using an anti-CD-66 antibody as part of a dose-reduced conditioning regimen, which was followed by a T-cell-depleted graft. 20 patients with a median age of 63 years suffering from acute leukaemia (n=17) or myelodysplastic syndrome (n=3) received the antibody labelled either with 188Rhenium (n=8) or with 90Yttrium (n=12) during conditioning. Radioimmunotherapy provided a mean dose of 21.9 (+/-8.4) Gy to the bone marrow with a significantly higher dose when 90Yttrium was used. Additional conditioning was fludarabine-based plus anti-thymocyte globulin in matched related donor transplants (n=11), or plus melphalan in matched unrelated donor transplants (n=9). Regimen-related toxicity was low, with two patients developing three episodes of grade III organ toxicity. All patients engrafted, grade II-IV acute graft-versus-host disease (GvHD) was observed in one patient (5%) and chronic GvHD in three patients (15%). The cumulative incidence of non-relapse mortality was 25%, the cumulative incidence of relapse 55%. The probability of survival was estimated to be 70% at 1 year and 52% at 2 years post-transplant, although no plateau was reached afterwards. In conclusion, radioimmunotherapy using the anti-CD66 antibody was feasible and safe in our elderly patient group and provided a high marrow dose.
Subject(s)
Antibodies, Monoclonal/therapeutic use , Antigens, CD/immunology , Antigens, Differentiation/immunology , Hematologic Diseases/therapy , Radioimmunotherapy/methods , Radioisotopes/therapeutic use , Transplantation Conditioning/methods , Aged , Antilymphocyte Serum/therapeutic use , Antineoplastic Agents/therapeutic use , Cell Adhesion Molecules , Female , Follow-Up Studies , Hematologic Diseases/radiotherapy , Hematologic Diseases/surgery , Humans , Immunosuppressive Agents/therapeutic use , Leukemia/radiotherapy , Leukemia/surgery , Leukemia/therapy , Lymphocyte Depletion , Male , Melphalan/therapeutic use , Middle Aged , Myelodysplastic Syndromes/radiotherapy , Myelodysplastic Syndromes/surgery , Myelodysplastic Syndromes/therapy , Radiometry , Rhenium/therapeutic use , Stem Cell Transplantation , Survival Rate , Transplantation, Homologous , Treatment Outcome , Vidarabine/analogs & derivatives , Vidarabine/therapeutic use , Yttrium Radioisotopes/therapeutic useSubject(s)
Bone Marrow Cells/pathology , Hematopoiesis, Extramedullary , Myelodysplastic Syndromes/pathology , Peritoneum , Primary Myelofibrosis/pathology , Ascites/pathology , Fatal Outcome , Hematopoiesis, Extramedullary/radiation effects , Humans , Male , Megakaryocytes/pathology , Middle Aged , Myelodysplastic Syndromes/radiotherapy , Primary Myelofibrosis/radiotherapy , Reticulin/ultrastructureABSTRACT
The prognosis of patients with acute myeloid leukaemia (AML) has improved considerably by introduction of aggressive consolidation chemotherapy and haematopoietic stem cell transplantation (SCT). Nevertheless, only 20-30% of patients with AML achieve long-term disease-free survival after SCT. The most common cause of treatment failure is relapse. Additionally, mortality rates are significantly increased by therapy-related causes such as toxicity of chemotherapy and complications of SCT. Including radioimmunotherapies in the treatment of AML and myelodyplastic syndrome (MDS) allows for the achievement of a pronounced antileukaemic effect for the reduction of relapse rates on the one hand. On the other hand, no increase of acute toxicity and later complications should be induced. These effects are important for the primary reduction of tumour cells as well as for the myeloablative conditioning before SCT. This paper provides a systematic and critical review of the currently used radionuclides and immunoconjugates for the treatment of AML and MDS and summarizes the literature on primary tumour cell reductive radioimmunotherapies on the one hand and conditioning radioimmunotherapies before SCT on the other hand.
Subject(s)
Leukemia, Myeloid, Acute/radiotherapy , Myelodysplastic Syndromes/radiotherapy , Radioimmunotherapy , Humans , Recurrence , Reproducibility of ResultsABSTRACT
PURPOSE: Total body irradiation (TBI) with and without additional radioimmunotherapy (RIT) was examined for renal toxicity after stem cell transplantation. PATIENTS AND METHODS: Serum creatinine levels of 35 patients (15 female, 20 male, median age 40.5 years, range 17-60 years) after TBI alone and of 23 patients (eight female, 15 male, median age 47, range 16-58 years) after TBI with additional RIT were determined between 10/1997 and 11/1999. TBI was performed by external-beam radiotherapy in six fractions over 3 days with renal doses of 12 Gy in the TBI-alone group and 6 Gy in the group with additional RIT. The mean kidney dose due to the (188)Re-radiolabeled antibody was estimated to be 8.3 Gy (2.3-11.6 Gy). RESULTS: Within 12 months after treatment, creatinine levels increased from 77 mmol/l (SD +/- 11) to 89 mmol/l (SD +/- 20) for TBI alone and from 78 mmol/l (SD +/- 13) to 144 mmol/l (SD +/- 52) for combined TBI and RIT. CONCLUSION: Despite a 50% reduction of the external-beam contribution to the kidney dose, the application of approximately 10 GBq (188)Re-labeled anti-CD66 monoclonal antibody with a calculated renal dose of 8.3 Gy (range 2.3-11.5 Gy) led to renal toxicity, as reported previously. In the absence of a positive dose-response relationship for the (188)Re-labeled antibody, the observation may be explained by an underestimation of the biologically effective dose and the inaccuracy of the dose determination at the glomerular level.
Subject(s)
Kidney/radiation effects , Leukemia/therapy , Radioimmunotherapy , Stem Cell Transplantation , Whole-Body Irradiation , Adolescent , Adult , Animals , Creatinine/blood , Dose Fractionation, Radiation , Female , Follow-Up Studies , Graft vs Host Disease/prevention & control , Humans , Leukemia/radiotherapy , Leukemia, Lymphocytic, Chronic, B-Cell/radiotherapy , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/radiotherapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Leukemia, Myeloid, Acute/radiotherapy , Leukemia, Myeloid, Acute/therapy , Male , Middle Aged , Myelodysplastic Syndromes/radiotherapy , Myelodysplastic Syndromes/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/radiotherapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Radiation Dosage , Radioisotopes/administration & dosage , Radiotherapy Dosage , Rats , Rhenium/administration & dosage , Time FactorsABSTRACT
BACKGROUND: Extramedullary hematopoiesis is a response of the organism to a deficient production of blood-forming cells within the bone marrow. It may coincide with some hematologic diseases. Two patients with paravertebral mass lesions representing extramedullary hematopoiesis are discussed. Characteristic findings of extramedullary hematopoiesis are presented along with a review of the literature on this topic. CASE REPORTS: A 76-year-old male with a known myelodysplastic syndrome presented with pneumonia. In addition, he had symptoms of a cauda equina syndrome with complaints of pain and hypesthesia of the lower limbs as well as urinary retention. A 63-year-old female presented with aggravated complaints of the lower thorax, low back pain radiating to the upper left leg, and dysesthesia of both feet. In her past medical history, she had polycythemia vera and a splenectomy. Both patients showed paravertebral and intraspinal lesions located in the thoracic and sacral spine which were regarded as extramedullary hematopoiesis according to the imaging findings in MRI and CT. Radiation therapy showed marked improvement in their neurologic complaints following the initial sessions. CONCLUSION: Clinical presentation, knowledge of the underlying disease and of imaging findings are essential in the diagnosis of extramedullary hematopoiesis. MRI is the imaging modality of choice in the primary diagnosis of extramedullary hematopoiesis. Possible extension of the disease into the intraspinal space can be evaluated with high accuracy and differential diagnosis can be facilitated. In addition, MRI is of use in the accurate planning of radiation fields as well as during follow-up of extramedullary hematopoiesis.
Subject(s)
Hematopoiesis, Extramedullary , Myelodysplastic Syndromes , Polycythemia Vera , Aged , Diagnosis, Differential , Follow-Up Studies , Hematopoiesis, Extramedullary/radiation effects , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Myelodysplastic Syndromes/complications , Myelodysplastic Syndromes/diagnosis , Myelodysplastic Syndromes/diagnostic imaging , Myelodysplastic Syndromes/radiotherapy , Polycythemia Vera/complications , Polycythemia Vera/diagnosis , Radiography, Thoracic , Radiotherapy Dosage , Time Factors , Tomography, Spiral ComputedABSTRACT
Myelodysplastic syndrome (MDS) is a clonal disorder of hematopoietic stem cells. To investigate whether chromosomal instability and/or DNA repair defects are involved in the development of MDS, we measured the micronucleus (MN) frequency in peripheral blood lymphocytes exposed to various doses of X-rays, using a cytokinesis-block micronucleus assay. The spontaneous MN frequencies in RAEB and RAEB-T patients were significantly higher than those in normal individuals (P = 0.0224, P = 0.008, respectively). Also, the X-ray-induced MN frequencies in RA/RARS, RAEB, and RAEB-T patients were significantly higher than those in normal individuals (P = 0.007, P = 0.003, P = 0.003, respectively, at 2 Gy). In order to elucidate the cause of unusual radiosensitivity, we measured the expression levels of nucleotide excision repair (NER) genes in peripheral blood mononuclear cells using a RT-PCR method. Reduction of NER gene expression was found in only one of 10 patients with low risk MDS, but in four of 11 patients with high risk MDS. Our data suggest that chromosomal instability and DNA repair defects may be involved in the pathophysiology of disease progression of MDS.
Subject(s)
Chromosome Aberrations , Endonucleases , Myelodysplastic Syndromes/genetics , Myelodysplastic Syndromes/radiotherapy , Radiation Tolerance , Adult , Aged , Aged, 80 and over , DNA Primers/chemistry , DNA Repair , DNA-Binding Proteins/genetics , Dose-Response Relationship, Radiation , Drosophila Proteins/genetics , Female , Humans , Karyotyping , Lymphocytes/blood , Lymphocytes/pathology , Male , Micronucleus Tests , Middle Aged , Nuclear Proteins , Proteins/genetics , RNA, Messenger/metabolism , RNA, Neoplasm/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors , X-RaysSubject(s)
Antineoplastic Agents/adverse effects , Chromosome Aberrations/chemically induced , Leukemia, Myeloid, Acute/drug therapy , Leukemia, Myeloid, Acute/radiotherapy , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/radiotherapy , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Child , Child, Preschool , Chromosome Aberrations/statistics & numerical data , Female , Humans , Infant , Leukemia, Myeloid, Acute/chemically induced , Leukemia, Myeloid, Acute/genetics , Male , Middle Aged , Myelodysplastic Syndromes/chemically induced , Myelodysplastic Syndromes/geneticsABSTRACT
Granulocytic sarcoma is a rare extramedullary malignant mass composed of primitive cells of the granulocytic lineage. It can arise from any part of the body and is frequently associated with haematological diseases, commonly acute myeloid leukaemia. Rarely, it has been found in conjunction with myelodysplastic syndrome. We report a case of cutaneous granulocytic sarcoma in a 73-year-old lady. The patient presented with a two-month history of multiple skin nodules which were confirmed by skin biopsy to be granulocytic sarcoma. Bone marrow examination was consistent with myelodysplastic syndrome. Localised radiotherapy to the skin lesions were given. She died from septicaemia six months after presentation. The management of this condition presents a diagnostic and therapeutic dilemma for both the pathologist and physician. In cases which are poorly differentiated as in this case, histological diagnosis is particularly difficult. Its definitive diagnosis would then require the additional use of a broad panel of immunohistochemical and cytochemical stains.
Subject(s)
Leukemia, Myeloid/diagnosis , Myelodysplastic Syndromes/diagnosis , Skin Neoplasms/diagnosis , Aged , Fatal Outcome , Female , Humans , Leukemia, Myeloid/radiotherapy , Myelodysplastic Syndromes/radiotherapy , Skin Neoplasms/radiotherapyABSTRACT
UNLABELLED: Amifostine (WR-2721) is a cytoprotective agent that protects a broad range of normal tissues from the toxic effects of chemotherapy and radiotherapy without attenuating tumour response. This selective protection is due to the greater conversion and uptake of the active metabolite, WR- 1065, in normal versus neoplastic tissues. In a pivotal phase III trial, 242 patients with advanced ovarian cancer were randomised to receive treatment with cisplatin 100 mg/m2 and cyclophosphamide 1000 mg/m2 every 3 weeks with or without pretreatment with intravenous amifostine 910 mg/m2. Over 6 cycles of therapy, amifostine significantly reduced haematological, renal and neurological toxicities: treatment delays, treatment discontinuation and days in hospital related to these adverse events were also significantly reduced in patients receiving amifostine versus patients receiving chemotherapy alone. In another randomised phase III trial in 303 patients with head and neck cancer undergoing irradiation therapy (total dose 50 to 70Gy), pretreatment with intravenous amifostine 200 mg/m2 significantly reduced the incidence of acute and late grade > or =2 xerostomia. However, mucositis was not significantly reduced in amifostine recipients compared with patients receiving radiotherapy alone, although this has been shown in smaller randomised trials. Amifostine (340 mg/m2) also provided significant protection against pneumonitis and oesophagitis in patients with lung cancer receiving thoracic irradiation in a preliminary report from a phase III trial (n = 144). Other studies have demonstrated protective effects of amifostine in other tumour types and other chemotherapy, radiation and radiochemotherapy regimens; however, evidence is still limited in these indications. No evidence of tumour protection by amifostine has been demonstrated in any clinical trials. Amifostine has also been shown to stimulate haematopoietic stem cells and has been investigated as a therapy for patients with myelodysplastic syndrome in number of small preliminary studies. At the recommended dose and schedule, amifostine is generally well tolerated. Adverse effects are usually reversible and manageable and those most frequently experienced include nausea and vomiting, transient hypotension and somnolence and sneezing. CONCLUSION: The results of phase III trials have confirmed the safety and efficacy of amifostine as a cytoprotectant to ameliorate cisplatin-induced cumulative renal toxicity, for which it is the only agent proven to be effective, and neutropenia in patients with advanced ovarian cancer, and to reduce xerostomia in patients with head and neck cancer receiving irradiation therapy. Depending on the outcome of numerous ongoing clinical trials, amifostine may eventually find broader clinical applications, both as a cytoprotectant and as a potential therapy in myelodysplastic syndrome.
Subject(s)
Amifostine , Cytoprotection/drug effects , Myelodysplastic Syndromes/drug therapy , Radiation-Protective Agents , Amifostine/economics , Amifostine/pharmacokinetics , Amifostine/pharmacology , Amifostine/therapeutic use , Animals , Drug Interactions , Economics, Pharmaceutical , Half-Life , Humans , Metabolic Clearance Rate , Mice , Myelodysplastic Syndromes/radiotherapy , Radiation-Protective Agents/economics , Radiation-Protective Agents/pharmacokinetics , Radiation-Protective Agents/pharmacology , Radiation-Protective Agents/therapeutic useABSTRACT
Delivery of targeted hematopoietic irradiation using radiolabeled monoclonal antibody may improve the outcome of marrow transplantation for advanced acute leukemia by decreasing relapse without increasing toxicity. We conducted a phase I study that examined the biodistribution of (131)I-labeled anti-CD45 antibody and determined the toxicity of escalating doses of targeted radiation combined with 120 mg/kg cyclophosphamide (CY) and 12 Gy total body irradiation (TBI) followed by HLA-matched related allogeneic or autologous transplant. Forty-four patients with advanced acute leukemia or myelodysplasia received a biodistribution dose of 0.5 mg/kg (131)I-BC8 (murine anti-CD45) antibody. The mean +/- SEM estimated radiation absorbed dose (centigray per millicurie of (131)I) delivered to bone marrow and spleen was 6.5 +/- 0.5 and 13.5 +/- 1.3, respectively, with liver, lung, kidney, and total body receiving lower amounts of 2.8 +/- 0.2, 1.8 +/- 0.1, 0.6 +/- 0.04, and 0.4 +/- 0.02, respectively. Thirty-seven patients (84%) had favorable biodistribution of antibody, with a higher estimated radiation absorbed dose to marrow and spleen than to normal organs. Thirty-four patients received a therapeutic dose of (131)I-antibody labeled with 76 to 612 mCi (131)I to deliver estimated radiation absorbed doses to liver (normal organ receiving the highest dose) of 3.5 Gy (level 1) to 12.25 Gy (level 6) in addition to CY and TBI. The maximum tolerated dose was level 5 (delivering 10.5 Gy to liver), with grade III/IV mucositis in 2 of 2 patients treated at level 6. Of 25 treated patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), 7 survive disease-free 15 to 89 months (median, 65 months) posttransplant. Of 9 treated patients with acute lymphoblastic leukemia (ALL), 3 survive disease-free 19, 54, and 66 months posttransplant. We conclude that (131)I-anti-CD45 antibody can safely deliver substantial supplemental doses of radiation to bone marrow (approximately 24 Gy) and spleen (approximately 50 Gy) when combined with conventional CY/TBI.
Subject(s)
Antibodies/administration & dosage , Antineoplastic Agents, Alkylating/administration & dosage , Bone Marrow Transplantation , Cyclophosphamide/administration & dosage , Leukemia/drug therapy , Leukemia/radiotherapy , Leukocyte Common Antigens/immunology , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/radiotherapy , Whole-Body Irradiation , Acute Disease , Adolescent , Adult , Combined Modality Therapy , Disease-Free Survival , Female , Graft Survival , Humans , Iodine Radioisotopes , Leukemia/immunology , Male , Middle Aged , Myelodysplastic Syndromes/immunology , Transplantation, Autologous , Transplantation, HomologousABSTRACT
BACKGROUND: As more pediatric patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) survive, comparison of the late effects of various therapies becomes increasingly important. This study of survivors of AML is the largest to date comparing the late effects of patients treated with chemotherapy (CT) with or without irradiation (RT) or CT followed by bone marrow transplantation (BMT). PROCEDURE: In a retrospective review of 228 patients with AML or MDS from 1970 to 1995, 62 survived and had follow-up data available more than 1 year following completion of therapy. Ten patients with Down syndrome were excluded. Twenty-six received CT and 26 underwent BMT. Weight and height Z scores, endocrine, ophthalmologic, renal, and cardiac function following CT +/- RT or BMT +/- total body irradiation (TBI) were compared at a mean follow-up of 7.4 and 5.6 years, respectively. RESULTS: Both groups experienced a decrement in height and increase in weight. The mean height Z score in the CT group fell from -0.29 to -0.72 (P = 0.02) and mean weight Z score rose from -0.06 at diagnosis (T0) to 0.51 at last follow-up (T2) (P = 0.02), a finding no longer significant when patients who received RT were excluded. The mean height Z score in the BMT group fell from -0.17 at TO to -0.65 at T2 (P = 0.02), while the mean weight rose from 0.29 at T0 to 0.84 at T2, (P = 0.07). Six of 9 BMT adolescent girls experienced ovarian failure versus 0 of 11 girls treated with CT (P = 0.002). Seven adolescent CT males and seven BMT males showed normal pubertal progression. Two BMT patients require thyroid hormone supplementation, and one receives growth hormone. Six BMT patients and one CT patient developed cataracts, all of whom received irradiation (P = 0.10). Serum creatinine level, hypertension, or left ventricular shortening fraction were not different in the two groups. One BMT patient has chronic graft versus host disease. CONCLUSIONS: Growth, renal, and cardiac functions were similar in the two groups. The need for estrogen supplementation was more frequent following BMT. Recommendations concerning therapy for AML should depend on the probability of cure.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation , Leukemia, Myeloid/drug therapy , Leukemia, Myeloid/therapy , Myelodysplastic Syndromes/drug therapy , Myelodysplastic Syndromes/therapy , Acute Disease , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Cataract/etiology , Child , Child, Preschool , Chronic Disease , Combined Modality Therapy , Cranial Irradiation/adverse effects , Female , Follow-Up Studies , Graft vs Host Disease/etiology , Heart/drug effects , Heart/physiopathology , Humans , Kidney/drug effects , Kidney/physiopathology , Leukemia, Myeloid/radiotherapy , Male , Myelodysplastic Syndromes/radiotherapy , Retrospective Studies , Treatment OutcomeABSTRACT
Therapy-related myelodysplastic syndrome (t-MDS) and acute nonlymphocytic leukemia (t-ANLL) are dramatic complications of cancer chemotherapy. Drugs like plant alkaloids or antimetabolites have not been reported to cause either t-MDS or t-ANLL. Monosomy 7(-7) and trisomy 8(+8) are among the most common abnormalities in myelodysplastic syndromes. Both abnormalities in two different clones of the same patient are very rarely reported. Such a myelodysplastic syndrome occurring shortly after treatment with an antimetabolite, the adenosine analogue cladribine (1-chlorodeoxadenosine), and involved field radiotherapy is reported here.